Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes without Previous Insulin Therapy.

Summary

In 795 insulin‑naïve adults with type 2 diabetes, once‑weekly efsitora was noninferior to daily glargine for HbA1c reduction (−1.19% vs −1.16%). Clinically significant/severe hypoglycemia was lower with efsitora (0.50 vs 0.88 events per participant‑year), with fewer dose adjustments (median 2 vs 8) and a lower total weekly dose.

Key Findings

• Noninferior HbA1c reduction at 52 weeks (−1.19% efsitora vs −1.16% glargine).
• Lower rate of clinically significant/severe hypoglycemia with efsitora (rate ratio 0.57, 95% CI 0.39–0.84).
• Fewer dose adjustments (median 2 vs 8) and lower total weekly insulin dose (−43.7 U/week).

Clinical Implications

Once‑weekly basal insulin initiation may simplify titration, reduce hypoglycemia, and improve adherence; clinicians should consider patient suitability and monitor fasting targets under the fixed escalation scheme.

Limitations

• Open-label design may introduce performance bias
• Insulin-naïve population; generalizability to insulin-experienced patients unknown

Future Directions

Assess long-term safety, patient-reported outcomes, and real-world adherence; compare head-to-head with other weekly basal insulins and with optimized daily titration strategies.